Prescriptions Blog: F.D.A. Delays Approval of New Diabetes Drug

Thursday, January 19, 2012 - 17:10 in Health & Medicine

Federal drug regulators are seeking more data from AstraZeneca and Bristol-Myers Squibb before deciding whether to approve dapagliflozin, a new drug aimed at Type 2 diabetes.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net